Key Developments: Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

1,858JPY
11 Jul 2014
Price Change (% chg)

¥3 (+0.16%)
Prev Close
¥1,855
Open
¥1,837
Day's High
¥1,874
Day's Low
¥1,837
Volume
1,875,900
Avg. Vol
2,139,839
52-wk High
¥2,007
52-wk Low
¥1,581

Search Stocks

Latest Key Developments (Source: Significant Developments)

Daiichi Sankyo announces resignation of chairman
Thursday, 15 May 2014 12:00am EDT 

Daiichi Sankyo Co Ltd:Says Takashi Shoda will resign from chairman of the board, on June 23.  Full Article

Sun Pharmaceutical Industries to acquire stake in Ranbaxy Laboratories from Daiichi Sankyo
Sunday, 6 Apr 2014 07:00pm EDT 

Daiichi Sankyo Co Ltd:Says Sun Pharmaceutical Industries Ltd will acquire stake in Ranbaxy Laboratories, which is a 63.4 pct-owned subsidiary of Daiichi Sankyo, through stock swap by December.The company will receive 0.8 share of Sun Pharma for each share of Ranbaxy, to hold about 9 pct stake in Sun Pharma.  Full Article

Daiichi Sankyo Co Ltd initiates Phase 3 ENSURE-AF study
Monday, 31 Mar 2014 07:01am EDT 

Daiichi Sankyo Co Ltd:Starts enrolling patients into the ENSURE-AF multinational phase 3 study.Study will evaluate the efficacy and safety of its investigational oral, once-daily direct factor Xa-inhibitor edoxaban.Compared to enoxaparin/warfarin for the prevention of stroke and other blood clot complications in patients with non-valvular atrial fibrillation (NVAF) undergoing electrical cardioversion (low-energy shocks to trigger normal heart rhythm).  Full Article

Daiichi Sankyo receives manufacturing and marketing approval for Efient tablet
Monday, 24 Mar 2014 02:00am EDT 

Daiichi Sankyo Co Ltd:Received approval from the Ministry of Health, Labor and Welfare in Japan for the antiplatelet agent Efient 3.75mg/5mg tablets (JAN: Prasugrel Hydrochloride), for the treatment of patients with ischemic heart disease undergoing percutaneous coronary intervention (PCI).Efient is an oral antiplatelet agent which reduces incidence of ischemic events in perioperative period of PCI by reducing platelet aggregation activity.  Full Article

Astellas Pharma Inc and Daiichi Sankyo Co Ltd form compound library sharing partnership
Wednesday, 19 Mar 2014 01:30am EDT 

Astellas Pharma Inc and Daiichi Sankyo Co Ltd:Says the companies would form compound library sharing partnership for about 400,000 selected compounds.Collaboration enables each party to promote new medicine research and development.This is first time that compound library partnership of this scale has been formed in Japan.Astellas and Daiichi Sankyo have compound libraries that are basis for their drug discovery research, and through High Throughput Screening (HTS), the companies can quickly and effectively search for potentially beneficial compounds to develop new drugs.This partnership will give each company access to qualitatively different compound libraries, which have been developed based on the targeting disease strategies of each company, allowing both companies to implement broader HTS to generate new drugs.Under this partnership, Astellas and Daiichi Sankyo will exchange about 400,000 selected compounds, including a number of synthetic compounds, from their respective compound libraries.Beginning April 1, for period of three years, both Astellas and Daiichi Sankyo will be able to implement broad HTS using shared compounds without restrictions on targeted disease areas.In line with partnership, each company will disclose sufficient information to allow receiving company to implement HTS independently.  Full Article

Daiichi Sankyo Co Ltd announces application of international financial reporting standards
Thursday, 30 Jan 2014 11:00pm EST 

Daiichi Sankyo Co Ltd:Says it will apply International Financial Reporting Standards (IFRS) as the new accounting method, to replace the current Japan Accounting Standards, starting from the financial report for fiscal year ending Mar. 2014.  Full Article

U.S. FDA bans on import active pharmaceutical ingredient produced by Daiichi Sankyo Co Ltd's subsidiary
Thursday, 23 Jan 2014 06:50pm EST 

Daiichi Sankyo Co Ltd:Says the United States Food and Drug Administration bans on import active pharmaceutical ingredient produced by Daiichi Sankyo Co Ltd's subsidiary effective Jan. 23 (U.S. time).  Full Article

Daiichi Sankyo Co Ltd Announces Phase 3 Clinical Trial Result of Once-Daily Edoxaban
Tuesday, 19 Nov 2013 06:00pm EST 

Daiichi Sankyo Co Ltd announced the results from the phase 3 ENGAGE AF-TIMI 48 study.This clinical trial found that the investigational, oral, once-daily direct factor Xa-inhibitor edoxaban met the primary efficacy endpoint of non-inferiority compared to warfarin for the prevention of stroke or systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (NVAF). Once-daily edoxaban also demonstrated reductions in bleeding compared to warfarin, achieving superiority for the principal safety endpoint.  Full Article

Daiichi Sankyo Co Ltd Amends Consolidated Full-year Forecast for FY 2014
Thursday, 31 Oct 2013 10:00pm EDT 

Daiichi Sankyo Co Ltd announced that it has raised the consolidated full-year forecast for revenue from JPY 1,080,000 million to JPY 1,110,000 million but lowered the forecast for operating profit from JPY 110,000 million to JPY 105,000 million, ordinary profit from JPY 100,000 million to JPY 90,000 million and affirmed the forecast for net profit of JPY 65,000 million for the fiscal year ending March 2014. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of JPY 1,073,300 million and net profit of JPY 62,570 million for the fiscal year ending March 2014.  Full Article

Daiichi Sankyo Co Ltd to Issue 3rd Series and 4th Series Unsecured Corporate Bonds
Wednesday, 11 Sep 2013 12:00am EDT 

Daiichi Sankyo Co Ltd announced that it has decided to issue the 3rd series unsecured corporate bonds, worth JPY 20 billion, each with a face value of JPY 100 million, a coupon rate of 0.549%, at the price of JPY 100 for every JPY 100, with a term of seven years, on September 18, 2013. The maturity date is September 18, 2020. The Company will also issue the 4th series unsecured corporate bonds, worth JPY 20 billion, each with a face value of JPY 100 million, a coupon rate of 0.846%, at the price of JPY 100 for every JPY 100, with a term of 10 years, on September 18, 2013. The maturity date is September 18, 2023.  Full Article

Search Stocks